☆ 4.3 Editorial Material

The potential of histone deacetylase inhibitors for the treatment of multiple myeloma

LEUKEMIA & LYMPHOMA (2008)

Journal

LEUKEMIA & LYMPHOMA

Volume 49, Issue 3, Pages 385-387

Publisher

TAYLOR & FRANCIS LTD

DOI: 10.1080/10428190801950058

Keywords

myeloma; neoplasia; histone; deacetylase

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Preclinical evidence supports the investigation of histone deacetylase inhibitors for the treatment of myeloma. Results from early studies demonstrate clinical activity and further studies investigating combination strategies should be explored.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Biochemistry & Molecular Biology

CC1007, a small molecular compound, suppresses multiple myeloma via upregulation of Nur77

Shicong Zhu, Cheng Xing, Guangsen Zhang, Hongling Peng, Zhihua Wang

Summary: In this study, CC1007 was found to inhibit the proliferation of multiple myeloma cells and induce apoptosis and cell cycle arrest. Additionally, CC1007 decreased the expression of MEF2C and HDAC7, disrupting their interaction and promoting the overexpression of Nur77. These findings suggest that CC1007 may be a promising drug for the treatment of multiple myeloma.

BIOORGANIC CHEMISTRY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension

Hae Jin Kee, Inkyeom Kim, Myung Ho Jeong

Summary: This article provides an overview of the pathogenesis of hypertension, current anti-hypertensive drugs, and the need for novel drugs. It focuses on the role and regulatory mechanisms of HDACs in hypertension and discusses the progress in developing HDAC inhibitors as potential therapeutic targets.

BIOCHEMICAL PHARMACOLOGY (2022)

Add to Collection

Article Oncology

Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma

Seiichi Okabe, Yuko Tanaka, Akihiko Gotoh

Summary: The study demonstrated that the dual inhibitor CUDC-907 targeting PI3K and HDAC could effectively suppress myeloma cells by inhibiting HDAC activity and reducing the expression of key proteins involved in cancer cell survival. Combination treatment of myeloma cells with CUDC-907 and carfilzomib showed increased cytotoxicity, indicating a potential strategy to enhance the effects of proteasome inhibitors against MM cells.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Review Chemistry, Medicinal

Histone deacetylase-based dual targeted inhibition in multiple myeloma

Angelica Ferro, Evangelia Pantazaka, Constantinos M. M. Athanassopoulos, Muriel Cuendet

Summary: Despite being an incurable disease, multiple myeloma (MM) can benefit from combined and targeted therapies, which have shown a decrease in drug resistance and an improvement in overall survival. Histone deacetylases (HDACs) play a crucial role in cancer treatment, including MM, and combining HDAC inhibitors with other regimens is of great interest. Recent advancements include the development of dual-inhibitor entities, which may reduce therapeutic doses and the risk of drug resistance.

MEDICINAL RESEARCH REVIEWS (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Histone Deacetylases and Their Isoform-Specific Inhibitors in Ischemic Stroke

Svetlana Demyanenko, Valentina Dzreyan, Svetlana Sharifulina

Summary: Cerebral ischemia is the second leading cause of death worldwide, requiring multimodal stroke therapy. Histone deacetylase inhibitors have shown to be effective in protecting the brain from ischemic damage by inducing neurogenesis and angiogenesis in damaged brain areas, promoting functional recovery after stroke.

BIOMEDICINES (2021)

Add to Collection

Article Chemistry, Medicinal

Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo

Yuqi Jiang, Jie Xu, Kairui Yue, Chao Huang, Mengting Qin, Dongyu Chi, Qixin Yu, Yue Zhu, Xiaohan Hou, Tongqiang Xu, Min Li, C. James Chou, Xiaoyang Li

Summary: The study focused on modifying HDAC inhibitors to deactivate the Michael reaction in order to improve their potency. Compound 11h showed significant improvements in both HDAC inhibitory activity and cell-based antitumor assay, demonstrating potential for clinical application and efficacy against AML.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Agricultural Engineering

Histone deacetylase inhibitors improve MeJA-induced ginsenoside production in ginseng adventitious roots

Xuefeng Lu, Tae Kyung Hyun

Summary: Post-translational histone modifications, such as histone acetylation, play key roles in regulating gene expression in plant growth, development, and stress responses. The research found that HDAC inhibitors led to hyperacetylation of histone H3, enhancing MeJA-induced ginsenoside production in ginseng adventitious roots. Additionally, the study identified specific PgHDACs that may serve as crucial factors in controlling MeJA-induced ginsenoside production.

INDUSTRIAL CROPS AND PRODUCTS (2021)

Add to Collection

Review Oncology

Potential of histone deacetylase inhibitors for the therapy of ovarian cancer

Fengyi Guo, Hongjing Wang

Summary: This review summarizes the classification and mechanisms of action of histone deacetylase and the clinical application of their inhibitors in ovarian cancer. Histone deacetylase inhibitors show promising potential as anti-cancer drugs, and combination therapy with other anticancer drugs for synergistic effects can improve efficacy.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Oncology

Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?

Amandine Badie, Christian Gaiddon, Georg Mellitzer

Summary: Our understanding of the identity of many cancers has greatly increased in recent years, leading to progress in early detection and treatment options. However, gastric cancer remains poorly treated with low survival rates. The lack of possibilities for early detection and the variations between tumors of gastric cancer patients are major challenges. Histone Deacetylases (HDACs) have been identified to be potentially related to gastric cancer. In this review, we summarize the current knowledge on the role of HDACs in gastric cancer development and their potential as early detection markers and targets for new treatment options.

CANCERS (2022)

Add to Collection

Review Pharmacology & Pharmacy

Fatty acids as histone deacetylase inhibitors: Old biochemistry tales in a new life sciences town

Meran Keshawa Ediriweera

Summary: Histone acetylation is a crucial epigenetic event and continues to be an area of great interest in biochemical research. The balance between histone acetyltransferases (HATs) and histone deacetylases (HDACs) is disrupted in various human cancers. Histone deacetylase inhibitors (HDACi) have shown promising results in restoring dysregulated histone acetylation profiles and are considered as potential anti-cancer therapeutics. Recent studies have identified odd-chain fatty acids as novel HDACi, further expanding the understanding of fatty acids in cancer therapy.

DRUG DISCOVERY TODAY (2023)

Add to Collection

Article Multidisciplinary Sciences

Multi-omics and machine learning reveal context-specific gene regulatory activities of PML::RARA in acute promyelocytic leukemia

William Villiers, Audrey Kelly, Xiaohan He, James Kaufman-Cook, Abdurrahman Elbasir, Halima Bensmail, Paul Lavender, Richard Dillon, Borbala Mifsud, Cameron S. Osborne

Summary: The PML-RARA gene fusion is the characteristic driver of Acute Promyelocytic Leukaemia (APL) and is known to bind to the genome. Here, the authors characterise the impact of PML-RARA on gene regulation in APL cell lines and patient samples using transcriptomics, epigenomics, and machine learning.

NATURE COMMUNICATIONS (2023)

Add to Collection

Review Oncology

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

Robert Jenke, Nina Ressing, Finn K. Hansen, Achim Aigner, Thomas Buch

Summary: Epigenetic changes can drive cancer malignancy, while histone deacetylase inhibitors (HDACis) hold promise as anticancer drugs due to their ability to target multiple pathways relevant to the disease.

CANCERS (2021)

Add to Collection

Review Pharmacology & Pharmacy

Histone deacetylase inhibitor-based oncolytic virotherapy: A promising strategy for cancer treatment

Ekta Shirbhate, Ravichandran Veerasamy, Sai H. S. Boddu, Amit K. Tiwari, Harish Rajak

Summary: One significant obstacle in cancer treatment is the decrease in drug efficacy and occurrence of adverse effects. Oncolytic viruses (OVs) have gained interest as a potential method to treat cancer due to their specificity for cancerous tissue and reduced likelihood of adverse effects. Clinical trials have shown that OVs have an acceptable safety profile and are effective in treating certain types of cancer, despite their limited availability. However, further advancements are needed to enhance tumor permeation and improve virus delivery in order to make oncolytic virotherapy more effective.

DRUG DISCOVERY TODAY (2022)

Add to Collection

Review Oncology

Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma

Jesus G. Berdeja, Jacob P. Laubach, Joshua Richter, Steve Stricker, Andrew Spencer, Paul G. Richardson, Ajai Chari

Summary: Panobinostat, an oral histone deacetylase inhibitor, shows promising potential in treating refractory multiple myeloma by resensitizing cells and exhibiting synergy with other antimyeloma drugs. Preclinical and clinical studies have demonstrated its efficacy in this aspect.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity

Shunda Li, Chunlong Zhao, Guozhen Zhang, Qifu Xu, Qian Liu, Wei Zhao, C. James Chou, Yingjie Zhang

Summary: The novel pyrrolo[2,3-d]pyrimidine-based HDAC inhibitors demonstrated potent inhibitory activities and selectivities against HDAC6, showing superior antiproliferative activity against human multiple myeloma cell lines while maintaining low cytotoxicity. In addition, one representative compound showed good metabolic stability and in vivo anti-multiple myeloma potency in a xenograft model.

BIOORGANIC CHEMISTRY (2021)

Add to Collection

Article Biophysics

Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)

Krystal Bergin, Cameron Wellard, Bradley Augustson, Rachel Cooke, Hilary Blacklock, Simon J. Harrison, Joy Ho, Tracy King, Hang Quach, Peter Mollee, Patricia Walker, Elizabeth Moore, Zoe McQuilten, Erica Wood, Andrew Spencer

Summary: Based on a cohort study in Australia/New Zealand, 76% of eligible multiple myeloma patients underwent autologous stem cell transplantation (ASCT), with non-recipients tending to be older, have more comorbidities, inferior performance status, and higher-risk MM. Regardless of age, ASCT showed a survival benefit in terms of progression-free survival and overall survival.

BONE MARROW TRANSPLANTATION (2021)

Add to Collection

Review Hematology

The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies

Dawn Swan, David Routledge, Simon Harrison

Summary: Treatment outcomes for multiple myeloma have improved significantly in the past decade, but patients with high-risk disease may still have poor outcomes. The role of immunotherapies, particularly bispecific antibodies (BsAbs), is growing rapidly with potential for improved results. However, these therapies also come with important safety considerations such as cytokine-release syndrome and neurotoxicity, which need to be carefully monitored in clinical trials.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Hematology

Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data

Sarah J. Halligan, Matthew J. Grainge, Nicolas Martinez-Calle, Christopher P. Fox, Mark J. Bishton

Summary: This study examined outcomes of relapsed sALCL patients in England after treatment with BV, and found that receiving BV as second-line therapy was associated with significantly improved survival. The majority of deaths occurred within 18 months post-BV treatment, with very few events occurring after this period.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Incidence and survival of haemophagocytic lymphohistiocytosis: A population-based cohort study from England

Joe West, Tim R. Card, Mark J. Bishton, Peter Lanyon, Lu Ban, Mary Bythell, Lucy Elliss-Brookes, Jessica J. Manson, Vasanta Nanduri, Judith Rankin, Rachel S. Tattersall, Colin J. Crooks

Summary: The study found an increase in the incidence of HLH in England between 2000 and 2016, with patients of all ages affected and significant differences in one-year survival rates.

JOURNAL OF INTERNAL MEDICINE (2022)

Add to Collection

Article Hematology

The development of a home-based therapeutic platform for multiple myeloma

Hayley Beer, David Routledge, Trish Joyce, Emma-Jane Furphy, Nella Combe, David Ritchie, Amit Khot, Seok Ming Lim, Michael Montalto, Simon J. Harrison

Summary: Multiple Myeloma (MM) is a rare but significant hematological malignancy, with traditional hospital-based treatment in Australia. However, innovative home-based treatment programs are being developed to allow patients to receive complex therapies at home, reducing time and burden on patients.

EXPERT REVIEW OF HEMATOLOGY (2021)

Add to Collection

Letter Biophysics

The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myeloma

Matthew J. Rees, Ashish Panigrahi, Simon J. Harrison, Andrew Spencer, Tiffany Khong, Simon Gibbs, Jay Hocking, Andrew Grigg, Daniela Zantomio

BONE MARROW TRANSPLANTATION (2022)

Add to Collection

Article Oncology

The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe

Mark Bishton, Scott Marshall, Jatinder Harchowal, Gilles Salles, Camille Golfier, Alessandra Tucci, Alicia Rodriguez Fernandez, Jose Javier Sanchez Blanco, Monica Bocchia, SooKyoung Kim, Young Nam Lee, Pier Luigi Zinzani

Summary: This study collected real-world data on the safety and effectiveness of rapid infusion of the rituximab biosimilar CT-P10 in patients with NHL and CLL. The results showed that the safety and effectiveness profile of RI-CT-P10 is similar to RI of reference rituximab.

HEMATOLOGICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy

Adam H. Lapidus, Mary Ann Anderson, Simon J. Harrison, Michael Dickinson, Tomas Kalincik, Arian Lasocki

Summary: CAR-T therapy is a promising immunotherapy for hematological malignancies, but its use is limited by significant rates of toxicity, including ICANS. Understanding the neuroimaging manifestations of ICANS can impact patient management.

LEUKEMIA & LYMPHOMA (2022)

Add to Collection

Article Hematology

Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Zoe McQuilten, Cameron Wellard, Elizabeth Moore, Bradley Augustson, Krystal Bergin, Hilary Blacklock, Simon Harrison, P. Joy Ho, Tracy King, Hang Quach, Peter Mollee, Brian Rosengarten, Patricia Walker, Erica Wood, Andrew Spencer

Summary: This study investigated the frequency and causes of early mortality in patients with newly diagnosed multiple myeloma. An analysis of patient registry data from Australia and New Zealand revealed that 9.1% of patients died within 12 months of diagnosis, with 4.5% of deaths occurring within 6 months. Age, performance status, serum albumin, cardiac disease, and International Staging System were identified as independent predictors of early mortality.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Hematology

Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013-2019

Hanhua Liu, Charles A. Stiller, Colin J. Crooks, Brian Rous, Mary Bythell, John Broggio, Judith Rankin, Vasanta Nanduri, Peter Lanyon, Tim R. Card, Lu Ban, Lucy Elliss-Brookes, Jennifer M. Broughan, Lizz Paley, Kwok Wong, Andrew Bacon, Mark Bishton, Joe West

Summary: This study provides the largest population-based epidemiological estimates of Langerhans cell histiocytosis (LCH) in England. The analysis reveals higher incidence and prevalence rates of LCH in children, as well as lower overall survival rates in patients aged 60 and above. Additionally, individuals in deprived areas have lower survival rates.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Letter Hematology

Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience

Adam Al-Hakim, James A. Poulter, Dina Mahmoud, Ailsa M. S. Rose, Suzanne Elcombe, Helen Lachmann, Catherine Cargo, Christopher J. A. Duncan, Mark Bishton, Venetia Bigley, Anjum Khan, Sinisa Savic

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Hematology

Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003-2018

Joe West, Peter Stilwell, Hanhua Liu, Lu Ban, Mary Bythell, Tim R. Card, Peter Lanyon, Vasanta Nanduri, Judith Rankin, Mark J. Bishton, Colin J. Crooks

Summary: The incidence of HLH in England has quadrupled between 2003 and 2018. Inflammatory rheumatological disease/IBD-associated HLH increased more among the younger age groups, while hematological malignancy-associated HLH had the largest increase in older age groups.

HEMASPHERE (2022)

Add to Collection

Article Hematology

Bendamustine plus rituximab for the treatment of Waldenstrom Macroglobulinemia: Patient outcomes and impact of bendamustine dosing

Suzanne O. Arulogun, Duncan Brian, Harshita Goradia, Aaron Cooney, Tobias Menne, RayMun Koo, Aideen T. O'Neill, Josephine M. I. Vos, Guy Pratt, Deborah Turner, Kirsty Marshall, Kate Manos, Claire Anderson, Maria Gavriatopoulou, Charalampia Kyriakou, Marie J. Kersten, Monique C. Minnema, Eirini Koutoumanou, Dima El-Sharkawi, Kim Linton, Dipti Talaulikar, Helen McCarthy, Mark Bishton, George Follows, Ashutosh Wechalekar, Shirley P. D'Sa

Summary: Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenstrom Macroglobulinemia (WM). This study aimed to evaluate the response rates and survival outcomes following BR, as well as the impact of depth of response and bendamustine dose. The results showed that achieving complete or very good partial response significantly improved survival, and total bendamustine dose was a predictor of progression-free survival (PFS) in both frontline and relapsed settings.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Hematology

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance

Allison Barraclough, James T. England, Diego Villa, Joel Wight, Greg Hapgood, Jason Conn, Nicole Wong Doo, Eric Wenlong Li, Michael Gilbertson, Briony Shaw, Mark J. Bishton, Malik Saeed, Sumita Ratnasingam, Chathuri Abeyakoon, Geoff Chong, Shin Hnin Wai, Matthew Ku, Hui-Peng Lee, Kathryn Fleming, Constantine Tam, Genevieve Douglas, Chan Y. Cheah, Zi Yun Ng, Tukten Rolfe, Anthony K. Mills, Nada Hamad, Helen Cashman, Mary Gleeson, Manjunath Narayana, Eliza A. Hawkes

Summary: Grade 3B follicular lymphoma (FL) is a rare subtype of FL, showing features of both 'low-grade' FL and diffuse large B-cell lymphoma (DLBCL). However, little is known about its clinical characteristics and outcomes due to limited research. This study analyzed 157 cases of G3BFL, finding that these patients had better overall survival and progression-free survival compared to DLBCL patients. They also had a younger age, better performance status, less extranodal disease, and more frequently had normal lactate dehydrogenase levels at baseline.

HAEMATOLOGICA (2023)

Add to Collection

Article Hematology

Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom

Adrian Minson, Nada Hamad, Pietro Di Ciaccio, Dipti Talaulikar, Matthew Ku, Sumita Ratnasingam, Chan Cheah, Costas K. Yannakou, Mark Bishton, Zi Yun Ng, Shivam Agrawal, Andrew Mcquillan, Anna Johnston, Emily Choong, Kimberly Wong, James Mcquillan, Ashley Beekman, Eliza Hawkes, Michael Dickinson

Summary: This study analyzed the treatment outcomes of 389 patients with mantle cell lymphoma and found that the rate of lymphoma-related death increased after each treatment line. Older age at diagnosis and early relapse after induction therapy were associated with a higher risk of death after second-line treatment. The results of this study support the exploration of novel therapies in earlier treatment lines.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.